Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
MN

NASDAQ · MNPR

Monopar Therapeutics Inc.

Healthcare · Biotechnology

$109.96

Down-$2.42 (-2.15%)

Updated Sep 11, 2026, 7:04 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
514.56M
P/E ratio
-0.16
Dividend yield
0.00%
52-week range
$50.07 – $124.82
Volume
94.15K
Avg. volume
123.73K

Price performance

MNPR price history

1M range · 20 trading sessions · Daily adjusted prices

MNPR closed at $109.96 after 20 trading sessions, down 0.41% for the selected period.

Last close
$109.96
Period change
-0.41%
Period low
$107.72
Period high
$123.84
Daily close
View OHLC price history
MNPR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$110.55$112.56$108.84$109.9694.15K
Sep 9, 2026$112.31$116.61$112.19$112.38111.4K
Sep 8, 2026$115.61$117.6075$113.27$114.38103.87K
Sep 4, 2026$117.85$119.00$116.21$117.5682.25K
Sep 3, 2026$117.44$121.02$115.07$118.55208.57K
Sep 2, 2026$119.04$121.00$114.2823$116.28203.35K
Sep 1, 2026$110.21$118.00$110.21$117.5795.17K
Aug 31, 2026$110.70$112.965$106.67$111.93141.85K
Aug 28, 2026$112.85$113.99$109.14$111.89221.55K
Aug 27, 2026$113.80$117.50$112.45$113.94142.83K
Aug 26, 2026$111.26$114.75$108.22$113.72123.77K
Aug 25, 2026$113.11$114.785$108.835$110.82133.19K
Aug 24, 2026$106.99$113.465$104.48$111.36239.19K
Aug 21, 2026$111.98$113.46$105.415$107.72176.42K
Aug 20, 2026$122.01$122.60$110.84$110.88208.1K
Aug 19, 2026$118.50$124.27$114.8082$123.84400.36K
Aug 18, 2026$115.00$120.00$113.79$119.05143.39K
Aug 17, 2026$113.35$117.00$111.60$116.49171.11K
Aug 14, 2026$109.04$113.56$107.78$113.04165.72K
Aug 13, 2026$110.17$113.24$108.23$110.41162.52K

Latest MNPR news

The latest Smart Investors Daily articles mentioning MNPR.

Stock researchCompany · Overview

MNPR research

Overview

Company profile and research snapshot.

Company profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$107.43
Implied upside
—
Analysts
—
MNPR recent ratings
DateFirmRatingTarget
Aug 13, 2026BarclaysOverweight—
Aug 13, 2026Cantor FitzgeraldNeutral—
Aug 12, 2026BTIGBuy—
Jul 22, 2026HC Wainwright & Co.Buy—
Jun 30, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 19, 2026

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By